- Home
- MDWD vs VBF Comparison
MDWD vs VBF Comparison
Compare MDWD & VBF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDWD
- VBF
- Stock Information
- Founded
- MDWD 2000
- VBF 1970
- Country
- MDWD Israel
- VBF United States
- Employees
- MDWD N/A
- VBF N/A
- Industry
- MDWD Medicinal Chemicals and Botanical Products
- VBF Trusts Except Educational Religious and Charitable
- Sector
- MDWD Health Care
- VBF Finance
- Exchange
- MDWD Nasdaq
- VBF Nasdaq
- Market Cap
- MDWD 184.8M
- VBF 177.3M
- IPO Year
- MDWD 2014
- VBF N/A
- Fundamental
- Price
- MDWD $19.83
- VBF $15.66
- Analyst Decision
- MDWD Strong Buy
- VBF
- Analyst Count
- MDWD 1
- VBF 0
- Target Price
- MDWD $25.00
- VBF N/A
- AVG Volume (30 Days)
- MDWD 69.9K
- VBF 45.5K
- Earning Date
- MDWD 03-20-2025
- VBF 01-01-0001
- Dividend Yield
- MDWD N/A
- VBF 5.18%
- EPS Growth
- MDWD N/A
- VBF N/A
- EPS
- MDWD N/A
- VBF N/A
- Revenue
- MDWD $19,720,000.00
- VBF N/A
- Revenue This Year
- MDWD $10.15
- VBF N/A
- Revenue Next Year
- MDWD $25.62
- VBF N/A
- P/E Ratio
- MDWD N/A
- VBF N/A
- Revenue Growth
- MDWD N/A
- VBF N/A
- 52 Week Low
- MDWD $11.04
- VBF $13.68
- 52 Week High
- MDWD $24.00
- VBF $16.27
- Technical
- Relative Strength Index (RSI)
- MDWD 63.06
- VBF 53.94
- Support Level
- MDWD $17.47
- VBF $15.44
- Resistance Level
- MDWD $18.79
- VBF $16.04
- Average True Range (ATR)
- MDWD 1.06
- VBF 0.18
- MACD
- MDWD 0.14
- VBF 0.04
- Stochastic Oscillator
- MDWD 96.41
- VBF 51.28
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
About VBF Invesco Bond Fund
Invesco Bond Fund is an independent investment management firm. Its investment objective is to seek interest income while conserving capital.